APUS vs PH · $2.4M cap vs P/E 28, rev $19.85B
Apimeds Pharmaceuticals US, Inc. (APUS) versus Parker-Hannifin Corporation (PH) — a side-by-side from cached financials, not a winner call.
Apimeds Pharmaceuticals US, Inc. (APUS) is a drug manufacturers - specialty & generic company listed on US.
Parker-Hannifin Corporation (PH) is a specialty industrial machinery company listed on US.
APUS does not have a complete income-statement cache yet.
Latest reported PH revenue for 2025-06-30 was $19.85B. Net income was $3.53B. PH currently screens at market cap $91.89B and trailing P/E 27.7.
APUS currently screens at market cap $2.4M. PH currently screens at market cap $91.89B and trailing P/E 27.7.
Not investment advice. Open the APUS and PH stock pages for the full models.
Not investment advice.